Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in patients with acute coronary syndrome in Poland: Modelling study from the hospital perspective

PharmacoEconomics

Volumn 21, Issue 10, 2003, Pages 737-748

  Orlewska, Ewa ^a   Budaj, Andrzej ^a   Tereszkowski Kaminski, Dariusz ^b  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b Uniformed Services Health Fund   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; HEPARIN;

ACCURACY; ACUTE CORONARY SYNDROME; ADULT; AGED; ALGORITHM; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; COST; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MODEL; MULTICENTER STUDY; POLAND; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSLUMINAL CORONARY ANGIOPLASTY;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CORONARY DISEASE; COST-BENEFIT ANALYSIS; DRUG COSTS; ENOXAPARIN; FEMALE; HEPARIN; HOSPITAL COSTS; HUMANS; MALE; MODELS, STATISTICAL; POLAND;

EID: 0043172228     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200321100-00005     Document Type: Article

References (41)

1. Telford AM, Wilson C. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet 1981; 1: 1225-8
2. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105-1 1
3. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827-30
4. Cohen M, Adams PC, Parry G. et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: primary endpoints analysis from the ATACS trial. Circulation 1994; 89: 81-8
5. Oler A, Whooley MA, Oler J, et al. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis. JAMA 1996; 276: 811-5
6. Braunwald E, Mark DB, Jones RH, et al. Unstable angina: diagnosis and management. Rockville (MD): Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute, Public Health Service, US Department of Health and Human Services, 1994. Clinical Practice Guideline Number 10
7. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part I: heparin. Circulation 1994; 89: 1449-68
8. Standardy Polskiego Towarzystwa Kardiologicznego: Choroba niedokrwienna serca (Polish Society of Cardiologists Standards: Ischaemic Heart Disease). Kardiologia Polska 1996; 46: 71-80
9. Weitz JL. Low-molecular-weight heparins. N Engl J Med 1997; 337 (10): 688-98
10. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5
11. Turpie AGG. Clinical trials of low molecular weight heparins. Eur Heart J 1999; 1 Suppl. R: R18-27
12. Gurfinkel EP, Manos EJ, Mejail RI, et al. Low-molecular-weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischaemia. J Am Coll Cardiol 1995; 26: 313-8
13. Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996; 347: 561-8
14. Klein W, Buchwald A, Hills SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin In unstable Coronary artery disease study (FRIC). Circulation 1997; 96: 61-8
15. The thrombolysis in myocardial infarction (TIMI) 11 A Trial Investigators. Dose ranging trial of enoxaparin for unstable angina: results of TIMI. J Am Coll Cardiol 1997; 29: 1474-82
16. Cohen M, Demers C, Gurfinkel EP, et al. Enoxaparin (low-molecular-weight heparin) versus unfractionated heparin for unstable angina and non-Q-wave myocardial infarction: primary endpoint results from Essence trial. N Engl J Med 1997; 337: 447-52
17. Antman EM, and the Thrombolysis in Myocardial Infarction (TIMI) Investigators. TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo controlled, parallel-group. Multicenter trial. Rationale, study design, and methods. Am Heart J 1998; 6 (Pt 3 Su): S353-60
18. FRAXIS study group. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction. FRAX.I.S. (FRAXiparine in Ischaemic Syndrome). Eur Heart J 1999; 20: 1553-62
19. Beguin S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. Thromb Haemost 1988; 60: 457-62
20. Beguin S, Mardiguian J, Lindhout T, et al. The mode of action of low molecular weight heparin preparation (PK10169) and two of its major components on thrombin generation in plasma. Thromb Haemost 1989; 61: 30-4
21. Hoppensteadt DA, Jeske W, Fareed J, et al. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin. Blood Coagul Fibrinolysis 1995; 6 Suppl. 1: S57-64
22. Xiao Z, Theroux P. Platelet activation with unfractioned heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998; 97: 251-6
23. Montalescot G, Philippe F, Ankri A, et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin: French Investigators of the ESSENCE Trial. Circulation 1998; 98: 294-9
24. Antman EM, Handin R. Low-molecular-weight heparins: an intriguing new twist with profound implications. Circulation 1998; 98: 287-9
25. Eikelboom JW, Anand SS, Malmberg K, et al. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000; 355: 1936-42
26. Michalis LK, Papamichail N, Katsouras C, et al. Enoxaparin versus tinzaparin in the management of unstable coronary artery disease (EVET Study) [abstract]. J Am Coll Cardiol 2001; 37: 365a
27. Antman EM, Fox KM. Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: proposed revisions. The International Cardiology Forum. Am Heart J 2000; 139: 461-75
28. Bertrand ME, Simoons ML, Fox KAA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 2002; 23: 1809-40
29. Braunwald E, Antman EM, Beasley JW., et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Unstable Angina). Available at URL: http://www.acc.org/clinical/guidelines/unstable/unstable.pdf [Accessed 2002 Mar 30]
30. Mark DB, Cowper A, Berkowitz SD, et al. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients. Results from ESSENCE randomised trial. Circulation 1998; 97: 1702-7
31. Fox KAA, Bosanquet N. Assessing the UK cost implications of the use of low molecular weight heparin in unstable coronary artery disease. Br J Cardiol 1998; 5 (2): 92-105
32. Bosanquet N, Fox KAA. Longer term economic benefits reflect improved clinical outcomes with enoxaparin versus unfractionated heparin in acute coronary syndromes: one-year data. Br J Cardiol 2001; 8 (1): 36-7
33. Detournay B, Huet X, Fagnani F, et al. Economic evaluation of enoxaparin sodium versus heparin in unstable angina: a French sub-study of the ESSENCE trial. Pharmacoeconomics 2000; 18 (1): 83-9
34. Balen RM, Carlo AM, Zed PJ, et al. Cost-effectiveness analysis of enoxaparin versus unfractionated heparin for acute coronary syndromes. A Canadian hospital perspective. Pharmacoeconomics 1999; 16 (5 Pt 2): 533-42
35. O'Brien BJ, Willan A, Blackhouse G, et al. Will the use of low-molecular-weight heparin (enoxaparin) in acute coronary syndrome patients save costs in Canada? Am Heart J 2000; 139: 423-9
36. Orlewska E, Mierzejewski P. Projekt polskich wytycznych przeprowadzania badań farmakoekonomicznych. (Polish guidelines for conducting pharmacoeconomic studies -project). Farmakoekonomika 2000; Suppl. 1: 3-11
37. The GRACE Investigators. Rationale and design of the GRACE (Global Registry of Acute Coronary Events) project: a multinational registry of patients hospitalised with acute coronary syndromes. Am Heart J 2001; 141: 190-9
38. Cennik hurtowni farmaceutycznej CEFARM (CEFARM pharmaceuticals wholesale price-list) lipiec-sierpień 2000. Bydgoszcz: PF CEFARM, 2000
39. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction TIMI 11B -ESSENCE meta-analysis. Circulation 1999; 100: 1602-8
40. Goodman SG, Cohen M, Bigonzi F, et al. Randomised trial of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one year results of the ESSENCE study. J Am Coll Cardiol 2000; 36: 693-8
41. Antman EM, Cohen M, McCabe C, et al. Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11b and ESSENCE. Eur Heart J 2002; 23: 308-14